Four Leaf Rover Turkey Tail Mushroom: Product Profile

Four Leaf Rover Turkey Tail Mushroom is a named branded product for Dogs; manufacturer positioning must be kept separate from independent clinical evidence.

Oral mushroom-extract powder mixed with food. Intended species: Dogs.

The 2024 official product guide lists organic Turkey Tail mushroom extract at 475 mg per 1/4 teaspoon and no inactive ingredients. The manufacturer describes whole mushrooms, double extraction, organic cultivation, and third-party testing for beta-glucans, pesticides, and heavy metals.

Four Leaf Rover markets Turkey Tail as a standalone mushroom supplement for immune-response and general wellness support, and as a companion to its multi-mushroom blend. Quality and testing claims describe the product but do not establish a cancer-treatment outcome.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

The official product guide cites the 2012 canine hemangiosarcoma PSP pilot. That study investigated a particular standardized polysaccharopeptide extract after splenectomy; it did not test Four Leaf Rover Turkey Tail. Therefore, the study is relevant background for research interest but cannot validate this finished product, its label amount, or use in other tumors. No controlled finished-product oncology trial was located.

Review mushroom allergy, gastrointestinal tolerance, autoimmune disease, immunosuppressive or immune-directed therapy, anticoagulants, surgery, pregnancy, organ disease, and duplicate mushroom products. Testing claims should be supported by current batch documentation where clinically important. Do not extrapolate a research dose from another extract or create a dose from a website summary.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

Marketed in the United States as an animal supplement, not identified as an FDA-approved animal drug. Organic certification or NASC participation, if present on a current package, relates to defined production or quality programs and does not equal FDA cancer-drug approval.

United States; International online market

Keep the current label and lot, define a supportive goal, and record appetite, stool, vomiting, skin signs, energy, and weight. The veterinarian should decide whether timing relative to medicines matters. Objective mass measurements, imaging, pathology, and treatment toxicity monitoring continue independently; lack of visible change does not prove benefit or failure.